Imatinib trough levels: A potential biomarker to predict cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia

被引：0
|
作者：
Natarajan, H. [1 ]
Kumar, L. [2 ]
Bakhshi, S. [2 ]
Sharma, A. [2 ]
Velpandian, T. [1 ]
Gogia, A. [2 ]
Gupta, Y. K. [1 ]
机构：
[1] All India Inst Med Sci, Clin Pharmacol, New Delhi, India
[2] All India Inst Med Sci, Med Oncol, New Delhi, India
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw586
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
335O
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?
    Goldman, J
    NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (03): : 126 - 127
  • [32] Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia
    Deenik, Wendy
    Janssen, Jeroen J. W. M.
    van der Holt, Bronno
    Verhoef, Gregor E. G.
    Smit, Willem M.
    Kersten, Marie Jose
    Daenen, Simon M. G. J.
    Verdouck, Leo F.
    Ferrant, Augustin
    Schattenberg, Anton V. M. B.
    Sonneveld, Pieter
    Kooy, Marinus van Marwijk
    Wittebol, Shulamit
    Willemze, Roelof
    Wijermans, Pierre W.
    Beverloo, H. Berna
    Lowenberg, Bob
    Valk, Peter J. M.
    Ossenkoppele, Gert J.
    Cornelissen, Jan J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (06): : 914 - 921
  • [33] Hematologic and cytogenetic response to imatinib mesylate in chronic myeloid leukemia
    Narayanan, G.
    Chacko, D. J.
    Koshy, A. A.
    Soman, L.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 82 : S18 - S18
  • [34] Hypophosphatemia During Imatinib Treatment of Newly Diagnosed Chronic Myeloid Leukemia Patients Is Associated with Better Response.
    Felipe Casado, Luis
    Massague, Isabel
    Giraldo, Pilar
    Perez-Encinas, Manuel
    de Paz, Raquel
    Martinez-Lopez, Joaquin
    Fores, Rafael
    Osorio, Santiago
    Jose Requena, Maria
    Palomera, Luis
    Jesus Penarrubia, Maria
    Burgaleta, Carmen
    Maestro, Begona
    Luis Steegmann, Juan
    BLOOD, 2009, 114 (22) : 459 - 460
  • [35] IFN-γ (interferon-gamma) Genotype Predict Cytogenetic and Molecular Response to Imatinib Therapy in Chronic Myeloid Leukemia
    Kim, Dong Hwan
    Kong, Jee Hyun
    Park, Silvia
    Jung, Chu Won
    Sriharsha, Lakshmi
    Xu, Wei
    Kamel-Reid, Suzanne
    Kim, Yeo-Kyeoung
    Kim, Hyeoung-Joon
    Lipton, Jeffrey H.
    BLOOD, 2009, 114 (22) : 857 - 857
  • [36] KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib
    D Marin
    I H Gabriel
    S Ahmad
    L Foroni
    H de Lavallade
    R Clark
    S O'Brien
    R Sergeant
    C Hedgley
    D Milojkovic
    J S Khorashad
    M Bua
    A Alsuliman
    A Khoder
    K Stringaris
    N Cooper
    J Davis
    J M Goldman
    J F Apperley
    K Rezvani
    Leukemia, 2012, 26 : 296 - 302
  • [37] KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib
    Marin, D.
    Gabriel, I. H.
    Ahmad, S.
    Foroni, L.
    de Lavallade, H.
    Clark, R.
    O'Brien, S.
    Sergeant, R.
    Hedgley, C.
    Milojkovic, D.
    Khorashad, J. S.
    Bua, M.
    Alsuliman, A.
    Khoder, A.
    Stringaris, K.
    Cooper, N.
    Davis, J.
    Goldman, J. M.
    Apperley, J. F.
    Rezvani, K.
    LEUKEMIA, 2012, 26 (02) : 296 - 302
  • [38] Plasma trough imatinib levels and molecular response in patients of chronic myeloid leukemia (CML): A single institution study from India.
    Malhotra, Hemant
    Sharma, Pratibha
    Bhargava, Shipra
    Rathode, Om Singh
    Malhotra, Bharti
    Gota, Vikram
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [39] LONG-TERM CLINICAL SIGNIFICANCE OF CYTOGENETIC CLONAL EVOLUTION IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH IMATINIB
    Lee, S. E.
    Choi, S. Y.
    Bang, J. H.
    Kim, S. H.
    Jang, E. J.
    Byeun, J. Y.
    Park, J. E.
    Jeon, H. R.
    Kim, M.
    Kim, D. W.
    HAEMATOLOGICA, 2012, 97 : 310 - 310
  • [40] Correlation of pharmacokinetic data with cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib - An analysis of IRIS study data.
    Larson, Richard A.
    Druker, Brian J.
    Guilhot, Francois
    O'Brien, Stephen G.
    Gathmann, Insa
    Riviere, Gilles J.
    So, Charlene
    Wang, Yanfeng
    BLOOD, 2006, 108 (11) : 131A - 131A
12345